0000000000370719

AUTHOR

Rossi C

showing 3 related works from this author

Chemical waves and pattern formation in the 1,2-dipalmitoyl-sn-glycero-3-phosphocholine/water lamellar system

2004

ChemistryMultidisciplinary{GEL}{MEDIA}{SPIRAL} {WAVES}{BELOUSOV-ZHABOTINSKII} {REACTION}{PROPAGATION}{BELOUSOV-ZHABOTINSKII} {REACTION}; Chemistry; Multidisciplinary; {GEL}; {MEDIA}; {PROPAGATION}; {SPIRAL} {WAVES}
researchProduct

Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study.

2005

Background & Aims: Transcatheter arterial chemoembolization (TACE) currently is used as a palliative treatment for patients with unresectable hepatocellular carcinoma (HCC), but its efficacy still is debated. Our aim was to assess the impact of TACE on patient survival and to identify prognostic factors for survival. Methods: Fifty-six cirrhotic patients with unresectable HCC undergoing at least :1 course of TACE were matched 1:1. for sex, age (in 5-year periods), parameters of Child-Pugh score, Okuda stage, and tumor type with a control group who had received only supportive care. Results: The 2 groups were comparable for cause of cirrhosis, alpha-fetoprotein serum levels, and Cancer of th…

Liver CirrhosisMaleCirrhosisTime FactorsPrognostic systemGastroenterologyOily chemoembolizationHepatic ArteryCause of DeathAscitesValidationMedicineStage (cooking)CIRRHOSISUnivariate analysisAntibiotics AntineoplasticLiver NeoplasmsGastroenterologyLiver-TransplantationMiddle AgedHEPATOCELLULAR CARCINOMA; CIRRHOSIS; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; SURVIVAL; SIDE EFFECTSPrognosisTreatment OutcomeItalyRandomized controlled trialHepatocellular carcinomaSURVIVALFemalemedicine.symptommedicine.medical_specialtyCarcinoma HepatocellularMultivariate-analysiTransarterial chemoembolizationInternal medicineSIDE EFFECTSCarcinomaHumansHEPATOCELLULAR CARCINOMAChemoembolization TherapeuticTranscatheter arterial chemoembolizationSurvival analysisAgedEpirubicinNeoplasm StagingCirrhosiHepatologybusiness.industrymedicine.diseaseSurvival AnalysisSurgeryLipiodol chemoembolizationTRANSCATHETER ARTERIAL CHEMOEMBOLIZATIONCase-Control StudiesMultivariate AnalysisbusinessFollow-Up StudiesClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct

A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

2011

Abstract Background HIV-1 genotypic susceptibility scores (GSSs) were proven to be significant prognostic factors of fixed time-point virologic outcomes after combination antiretroviral therapy (cART) switch/initiation. However, their relative-hazard for the time to virologic failure has not been thoroughly investigated, and an expert system that is able to predict how long a new cART regimen will remain effective has never been designed. Methods We analyzed patients of the Italian ARCA cohort starting a new cART from 1999 onwards either after virologic failure or as treatment-naïve. The time to virologic failure was the endpoint, from the 90th day after treatment start, defined as the firs…

OncologyMaleAdult; Anti-HIV Agents; Cohort Studies; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Proportional Hazards Models; Treatment Failure; Viral LoadHIV InfectionsCohort Studies0302 clinical medicineANTIRETROVIRAL THERAPYMedicineHIV Infection030212 general & internal medicineTreatment Failure0303 health sciencesHealth PolicyMiddle AgedViral Load3. Good healthComputer Science ApplicationsCensoring (clinical trials)CohortCombinationlcsh:R858-859.7Drug Therapy CombinationFemaleViral loadHumanResearch ArticleCartAdultmedicine.medical_specialtyAnti-HIV AgentsHIV-1; antiretroviral therapyHealth InformaticsSettore MED/17 - MALATTIE INFETTIVElcsh:Computer applications to medicine. Medical informatics03 medical and health sciencesDrug TherapyInternal medicineHumansSurvival analysisProportional Hazards Models030306 microbiologybusiness.industryProportional hazards modelAdult; Anti-HIV Agents; Cohort Studies; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Proportional Hazards Models; Treatment Failure; Viral Load; Health Informatics; Health PolicyANTIRETROVIRAL DRUGSAnti-HIV AgentHIVGENOTYPESDiscontinuationRegimenImmunologyProportional Hazards ModelHIV-1Cohort StudiebusinessBMC Medical Informatics and Decision Making
researchProduct